Melanotan 2

Melanotan 2, also widely known as MT2, is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the naturally occurring hormone responsible for regulating melanin production in the skin. ⁽¹⁾ Developed at the University of Arizona during the early 1990s as part of research into sunless tanning agents, Melanotan 2 has the chemical structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 and is registered under CAS number 121062-08-6. ⁽²⁾

Unlike its linear predecessor, Melanotan 1 (afamelanotide), MT2 features a cyclic lactam bridge that confers several distinct pharmacological properties: greater metabolic stability, increased potency, and the ability to cross the blood-brain barrier. ⁽²⁾ This structural modification makes Melanotan 2 a non-selective agonist of melanocortin receptors MC1R, MC3R, MC4R, and MC5R, meaning it activates multiple receptor subtypes throughout the body rather than selectively targeting skin pigmentation alone. ^(1,2) This non-selective profile accounts for the broader range of effects observed in research beyond pigmentation, including appetite modulation and sexual function changes.

Melanotan 2 occupies an important position in the history of melanocortin pharmacology. Its development led directly to bremelanotide (PT-141). This MT2 metabolite was subsequently developed by Palatin Technologies and approved by the FDA in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. ⁽⁵⁾ Meanwhile, the pigmentation-focused branch of research produced afamelanotide (Melanotan 1), approved by the FDA in 2019 for erythropoietic protoporphyria. ⁽⁶⁾ MT2 itself has not received regulatory approval for any indication.

Healius supplies Melanotan 2 as a lyophilized (also referred to as lyophilized in US research literature) powder in 10mg vials, intended strictly for laboratory and research applications.

Melanotan 2 stimulates melanin production by binding to melanocortin-1 receptors (MC1R) on the surface of melanocytes, the specialized cells responsible for skin pigmentation. ⁽¹⁾ Upon binding, MT2 triggers the adenylate cyclase signaling cascade, increasing intracellular cyclic AMP (cAMP) levels. This activates protein kinase A (PKA), which phosphorylates cAMP response element-binding protein (CREB), ultimately driving transcription of microphthalmia-associated transcription factor (MITF). ⁽⁷⁾ MITF in turn regulates the expression of melanogenic enzymes, most importantly tyrosinase, the rate-limiting enzyme in melanin synthesis. ⁽⁷⁾

A critical distinction in melanogenesis is the shift between two types of melanin. Pheomelanin, a reddish-yellow pigment with lower photoprotective capacity, and eumelanin, a brown-to-black pigment that effectively absorbs ultraviolet radiation. MT2 activation of MC1R promotes eumelanin production over pheomelanin, resulting in darker pigmentation that provides greater natural photoprotection. ^(1,7) This eumelanin shift occurs even in individuals carrying MC1R gene variants that typically favor pheomelanin production, such as those with fair skin and red hair. ⁽⁸⁾

Because MT2 is a non-selective melanocortin agonist, it activates receptors beyond MC1R. MC3R and MC4R, expressed in the hypothalamus and other brain regions, are involved in regulating appetite, energy homeostasis, and sexual behavior. ^(1,9) MC4R activation has been specifically linked to appetite suppression through hypothalamic satiety signaling and to the modulation of sexual arousal pathways. These effects were significant enough to drive the development of bremelanotide as a standalone pharmaceutical. ⁽⁵⁾ MC5R, found in peripheral tissues, has been associated with exocrine function in certain experimental models. ⁽¹⁾

The blood-brain barrier permeability of MT2, conferred by its cyclic structure, enables the central nervous system effects observed with MT2 that are not observed with the linear Melanotan 1 analog. ⁽²⁾ This pharmacological distinction is fundamental to understanding why MT2 produces a broader spectrum of research endpoints than compounds with more selective MC1R activity.

The landmark human pigmentation study was conducted by Levine et al. and published in JAMA in 1991, demonstrating that subcutaneous administration of a potent synthetic melanotropin could induce measurable skin tanning in human volunteers. ⁽⁸⁾ This was the first published evidence that exogenous melanocortin receptor activation could produce visible pigmentation changes in a controlled clinical setting.

Subsequent clinical work refined the dosing parameters. A Phase I study evaluated MT2 at escalating subcutaneous doses of 0.01 to 0.03 mg/kg, administered on alternating days over 2 weeks, in healthy male volunteers. Two of three subjects showed increased pigmentation in the face, upper body, and buttocks, as measured by quantitative reflectance spectroscopy, with tanning persisting one week after the final dose. The recommended Phase I dose was established at 0.025 mg/kg per day. ⁽³⁾ Additional research by Dorr et al. in Archives of Dermatology ⁽²⁰⁰⁴⁾ examined the combination of MT2 with solar UV radiation, confirming enhanced tanning response in human volunteers receiving the peptide compared to UV exposure alone. ⁽¹⁰⁾

The melanogenic effect of MT2 is dose-dependent and cumulative. Research indicates that pigmentation typically becomes visually apparent within one to two weeks of consistent administration, with progressive deepening over subsequent weeks. ^(3,10) The response varies with baseline skin type on the Fitzpatrick scale, with fairer-skinned individuals generally requiring longer loading periods to achieve visible results. Importantly, MT2 primes melanocytes for enhanced melanin production, but visible results are significantly amplified by concurrent UV exposure, as ultraviolet light activates the melanocytes that MT2 has stimulated. ⁽¹⁰⁾

An in vivo study published in 2020 produced a particularly noteworthy finding: topical MT2 administration dramatically slowed tumor growth in mice with pre-existing melanoma. ⁽¹¹⁾ The researchers found that MT2 inhibited melanoma cell migration, invasion, and colony formation without affecting cell proliferation, operating through MC1R-mediated upregulation of PTEN (phosphatase and tensin homolog) and suppression of the AKT/NF-kappaB signaling pathway. ⁽¹¹⁾ This finding adds complexity to the safety discussion and underscores the importance of continued research into MT2’s effects on melanocyte biology.

The non-selective melanocortin receptor activity of Melanotan 2 produces documented effects well beyond skin pigmentation. MC4R activation in the hypothalamus influences the neuroendocrine regulation of hunger and satiety, leading to appetite suppression and reduced food intake in both animal and human studies. ⁽⁹⁾ This effect is mediated through the same central melanocortin pathways targeted by obesity research, though MT2 itself has not been specifically studied as a weight management compound.

The sexual function effects of MT2 are among the most robustly documented in the clinical literature. In a double-masked, placebo-controlled crossover study of men with psychogenic erectile dysfunction, subcutaneous MT2 at 0.025 mg/kg-initiated erections in 8 of 10 participants, with a mean tip rigidity duration of 38 minutes compared to 3 minutes with placebo (p = 0.0045). ⁽⁴⁾ Sexual desire was significantly stronger after MT2 than placebo. ⁽⁴⁾ These findings were compelling enough to drive the development of bremelanotide. This MT2 derivative was subsequently approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. ⁽⁵⁾

Emerging research has explored MT2 in neurological contexts. A 2019 study by Minakova et al., published in PLoS ONE, demonstrated that Melanotan 2 reversed autistic features in a maternal immune activation mouse model of autism, including improvements in sociability deficits. ⁽¹²⁾ Melanocortin receptors (MC1R, MC3R, and MC4R) are expressed throughout the central nervous system in neural, glial, and endothelial cells, and melanocortin signaling has been studied in experimental models of neuroinflammation, ischemic injury, and synaptic plasticity. ⁽¹⁾ These findings position MT2 as a research tool with potential applications in neuroimmune and neurobehavioural investigation.

Anti-inflammatory properties have also been documented. Melanocortin receptor activation on immune cells, including monocytes, macrophages, and lymphocytes, has been associated with modulation of inflammatory mediator expression and regulation of the NF-kappaB pathway in multiple experimental systems. ⁽¹⁾

Transparent reporting of the safety profile is essential for any research compound, and Melanotan 2 has a documented side effect profile that researchers must understand before designing protocols. MT2 has not completed large-scale clinical safety trials, and it is not approved for human use by any regulatory authority. ^(6,13)

The most frequently reported acute effects in clinical studies are facial flushing and nausea, which typically occur within minutes of subcutaneous administration and resolve within hours. ^(3,4) These effects are generally transient and tend to diminish with continued use. Other commonly reported effects include fatigue, yawning, and appetite suppression. ⁽³⁾ In the erectile dysfunction study, nausea occurred frequently enough that 4 of 19 injections were associated with severe nausea, though none required treatment. ⁽⁴⁾

Changes to pigmented skin lesions are among the most clinically significant observations. MT2 broadly stimulates melanocytes, including those within existing moles (naevi, also spelled nevi in US literature). Deepening of mole color (also spelled color), the eruption of new naevi, and the development of atypical melanocytic naevi have been documented in multiple case reports and clinical observations. ^(13,14) These changes can make dermatological monitoring more difficult by altering the appearance of lesions that might otherwise be flagged during routine skin examination.

The relationship between MT2 and melanoma remains an area of active investigation, with no definitive resolution. A 2013 scientific review found no conclusive evidence that MT2 causes melanoma. ⁽¹⁴⁾ A 2021 review concluded that increased melanoma risk in MT2 users could probably be explained by greater UV exposure, as users who seek enhanced tanning often combine MT2 with sunbed use. ⁽¹⁵⁾ The 2020 in vivo study demonstrating MT2 suppression of melanoma progression adds further nuance. ⁽¹¹⁾ However, individual case reports have documented melanoma diagnoses in MT2 users, including a 2025 case report in Environmental Research associating nasal spray MT2 use with oral mucosal malignant melanoma. ^(14,16) Researchers should weigh this unresolved evidence carefully.

Rare but serious adverse events documented in the medical literature include renal infarction, as reported by Peters et al.  ⁽²⁰²⁰⁾, and rhabdomyolysis. ⁽¹⁷⁾ Priapism (prolonged, painful erection) has been reported as a consequence of MC4R-mediated sexual arousal effects. ^(4,13) These events, while uncommon, underscore the importance of appropriate protocol design and monitoring in any research involving MT2.

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies, and commercialization. Peptides. 2006; 27:921-930.

2. Hruby VJ, et al. Cyclic lactam alpha-melanotropin analogs of Ac-Nle4-cyclo [Asp5, D-Phe7, Lys10] alpha-melanocyte-stimulating hormone-(4-10)-amide with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. Journal of Medicinal Chemistry. 1995;38(18):3454-3461.

3. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-1784.

4. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-masked, placebo-controlled crossover study. Journal of Urology. 1998;160(2):389-393.

5. FDA approval of bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. FDA. 2019.

6. DermNet NZ. Melanotan II. Updated 2024.

7. Activation of MC1R by melanocortin peptides: adenylate cyclase/cAMP/PKA/CREB/MITF signaling cascade. (Synthesized from multiple sources, including Hadley 2006 and Creative Peptides review 2025.)

8. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730-2736.

9. Schioth HB, Marcus M. Melanocortin peptides as regulators of appetite and energy homeostasis. International Journal of Molecular Sciences. 2019.

10. Dorr RT, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology. 2004.

11. In vivo study demonstrating MT2 suppression of melanoma progression via MC1R-mediated PTEN upregulation and AKT/NF-kappaB pathway inhibition. 2020.

12. Minakova E, et al. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS ONE. 2019;14(1): e0210389.

13. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ. 2009;338: b556.

14. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014; 228:34-36.

15. Nelson ME, et al. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology. 2021.

16. Alsabbagh AY, et al. Melanotan II nasal spray: A possible risk factor for oral mucosal malignant melanoma? Environmental Research. 2025; 278:121646.

17. Peters B, et al. Melanotan II: A possible cause of renal infarction. 2020.

18. Therapeutic Goods Administration (TGA), Australia. Don’t risk using tanning products containing melanotan. 2025.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.